Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eylea Pricing is Eye-Opening: Regeneron Plays to CMS, Payors on Price; Docs with Terms

This article was originally published in RPM Report

Executive Summary

Choosing between doctors and payors in the “buy-and-bill” sector used to be easy – price to the doctor’s advantage. The higher the price, the larger the spread and the happier the drug company. Regeneron is bending that model towards the reimbursers (and Medicare, in particular) with Eylea. Regenero

You may also be interested in...



Finally A FIBCO, Regeneron Sets Its Sights On Eylea And Beyond

The better-than-expected performance of Regeneron’s first significant commercial drug, Eylea, has fueled the company’s ambitions to build a sustainable, risk-adjusted portfolio based on a mix of best-in-class and first-in-class new drugs. Getting to this point took a mixture of perseverance, astute science, opportunism, and savvy partnering.

Cutting Cost in Medicare: How About Considering Cost First?

A modest proposal for the austerity era: let the federal government factor cost into coverage decisions for Medicare Part B. For biopharma companies, that sounds like a terrible idea—but, in the long term, the alternatives just might be much worse.

Biopharma's Default Position: Drug Stocks Hold Up Against US Downgrade

Economists are fretting that the US may be heading into a “lost decade” of stagnation. Will those fears help Big Pharma investors finally end a lost decade of their own?

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS080923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel